- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 24.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings | 201 | GlobeNewswire (Europe) | Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)... ► Artikel lesen | |
| 16.12.25 | MAIA Biotechnology announces $1.51M private placement | 2 | Seeking Alpha | ||
| 16.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces $1.51 Million Private Placement | 3 | GlobeNewswire (USA) | ||
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates | 115 | GlobeNewswire (Europe) | CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA),... ► Artikel lesen | |
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer | 295 | GlobeNewswire (Europe) | Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE... ► Artikel lesen | |
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential | 4 | GlobeNewswire (USA) | ||
| 10.12.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.12.25 | MAIA Biotechnology, Inc.: MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach | 92 | GlobeNewswire (Europe) | CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) - The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade... ► Artikel lesen | |
| 01.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Directors | 1 | GlobeNewswire (USA) | ||
| 21.11.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 | 272 | GlobeNewswire (Europe) | Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO, Nov. 21, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 20.11.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.11.25 | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Maia Biotechnology stellt Studiendaten auf der SITC-Konferenz 2025 vor | 1 | Investing.com Deutsch | ||
| 07.11.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.10.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.10.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 228 | GlobeNewswire (Europe) | Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the... ► Artikel lesen | |
| 14.10.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.10.25 | MAIA Biotechnology announces $0.74M private placement | 2 | Seeking Alpha | ||
| 13.10.25 | MAIA Biotechnology raises $736,600 in private placement | 1 | Investing.com | ||
| 13.10.25 | MAIA Biotechnology sichert sich 736.600 US-Dollar durch Privatplatzierung | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 105,60 | -0,40 % | Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact | ||
| ABBVIE | 196,60 | +0,10 % | BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View | ||
| ABBOTT LABORATORIES | 105,58 | -0,25 % | What You Need to Know Ahead of Abbott Laboratories' Earnings Release | ||
| SCHOTT PHARMA | 15,100 | 0,00 % | Schott Pharma: Entwicklung und aktuelle Einschätzung | ||
| EDWARDS LIFESCIENCES | 73,55 | -0,59 % | Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System Wins FDA Approval | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) on Tuesday said its SAPIEN M3 mitral valve replacement system received U.S. Food and Drug Administration (FDA) approval for the treatment... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 27,500 | -1,08 % | Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs | FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase... ► Artikel lesen | |
| PENTIXAPHARM | 1,452 | -2,55 % | Pentixapharm: FDA-Feedback für Phase-3-Studie mit PentixaFor | Die Pentixapharm Holding AG hat im Rahmen eines Type-B-Pre-IND-Meetings mit der US-amerikanischen Food and Drug Administration (FDA) Feedback zur geplanten Phase-3-PANDA-Studie mit dem radiodiagnostischen... ► Artikel lesen | |
| CASSAVA SCIENCES | 1,789 | +1,42 % | Cassava Sciences, Inc.: Cassava Announces Agreement to Settle Securities Class Action Litigation | AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 129,00 | +0,74 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission | New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era... ► Artikel lesen | |
| MEDPACE | 479,60 | -0,62 % | Medpace Holdings - MEDP: Kapitalrendite besser als bei Iqvia, Thermo Fisher & Icon! | Kursziel 700 USD! Erwartungen übertroffen, Prognose angehoben! Medpace-Aktie (MEDP) mit Gap Ups nach den letzten beiden Quartalszahlen! Medpace (MEDP) - ISIN US58506Q1094 Rückblick: Ein Kursplus von... ► Artikel lesen | |
| ZEALAND PHARMA | 63,86 | -0,19 % | Zealand Pharma meldet 71,5 Millionen ausstehende Aktien zum Jahresende | ||
| UNITED THERAPEUTICS | 428,60 | +0,30 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| UCB | 235,00 | -0,59 % | Lee's Pharmaceutical Holdings Limited: Lee's Pharmaceutical Holdings Limited Acquires Staccato One Breath Technology Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights | Acquisition of Staccato One Breath Technology, a proprietary platform technology with broad therapeutic potentialSynergistic and complementary to Lee's Pharm's existing products pipeline... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 497,70 | -0,16 % | Arrowhead, BioNTech, Madrigal & Co: Biotech-Power für das Depot! | Das Börsenjahr 2025 stand natürlich ganz klar im Schatten der US-Technologieriesen wie Nvidia & Co. Darüber hinaus sorgten auch die Gold- und Silberaktien für Aufsehen, doch eine stark laufende Branche... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 63,74 | -0,78 % | BridgeBio-Aktie: No Brainer Club zelebriert +157% auf den Einstieg | Die Aktie unserer No Brainer Club-Empfehlung BridgeBio zählt derzeit zu den auffälligsten Gewinnern im Biotech-Sektor. Trotz eines rasanten Kursanstiegs eröffnet die Pipeline des Unternehmens weiterhin... ► Artikel lesen |
Das Unternehmen MAIA BIOTECHNOLOGY INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,515 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.